GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout
Revenues Up By 32%
Executive Summary
GlaxoSmithKline has just acquired a late-stage oncology asset, and sales of Shingrix are on the up again, but the outcome of its RSV vaccine study remains the main focus for 2022.
You may also be interested in...
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
Europe’s Big Pharma Players Begin Tricky 2022 In Style
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.
Recent US FDA Breakthrough Therapy Designations, From Mass Market Vaccines To Rare Diseases
Merck’s latest pneumococcal vaccine and Pfizer’s RSV vaccine notched new BTDs, along with Zambon’s inhaled antibiotic for non-CF bronchiectasis, Acer’s vascular Ehlers-Danlos syndrome drug and Dizal’s targeted lung cancer candidate.